A white blood cell that normally removes bacteria from the bloodstream helps Escherichia coli (E. coli) accumulate in the blood and enter the brain resulting in the deadly infection known as meningitis.
Prasadarao V. Nemani, PhD, a scientist at The Saban Research Institute at Children Hospital Los Angeles plans to find out how this happens with a grant of $1.65 million from the National Institutes of Health – National Institute of Neurological Disorders and Strokes.
Meningitis is the inflammation of the covering of the brain and spinal cord. Bacterial meningitis can be serious, leaving about one third of those who survive with permanent neurological problems. Escherichia coli K1 meningitis is the most common infection of the central nervous system in newborns.
The disease occurs when bacteria replicate and eventually break through the protective “blood-brain barrier.” A single layer of endothelial cells, the blood-brain barrier normally prevents bacteria from entering the brain. The molecular mechanisms allowing this build-up of E. coli and its eventual invasion of the brain are not well understood. Nemani’s research implicates a type of white blood cell called a “macrophage.” Macrophages normally remove invading organisms from the blood.
“It is as if the macrophage turns traitor,” said Nemani, who also serves as an associate professor of infectious disease at Childrens Hospital Los Angeles. “Instead of protecting the body, it helps the bacteria survive in the blood and enter the brain. What causes the macrophage to change? When we figure that out, we have the basis for preventing the build-up of bacteria and preventing meningitis.”
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.